Controlled Delivery of Nitric Oxide for Cancer Therapy.

Pharm Nanotechnol

Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.

Published: January 2020

Nitric oxide (NO) is a short-lived, endogenously produced, signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecular weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967185PMC
http://dx.doi.org/10.2174/2211738507666190429111306DOI Listing

Publication Analysis

Top Keywords

controlled delivery
8
nitric oxide
8
delivery nitric
4
oxide cancer
4
cancer therapy
4
therapy nitric
4
oxide short-lived
4
short-lived endogenously
4
endogenously produced
4
produced signaling
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!